ArticleFrontiers in psychiatry2020
Mitragynine Attenuates Morphine Withdrawal Effects in Rats-A Comparison With Methadone and Buprenorphine.
Article in Frontiers in psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans.Human psychopharmacology · 2022Pooled it
- Investigating Opioid Receptor Activity through Biocatalytic Halogenation and Oxidation of Mitragynine.ACS chemical biology · 2026Article
- A Review of Kratom Product Evolution and Its Associated Health Outcomes.Substance abuse and rehabilitation · 2026Review
- Article
- Discovery of rhynchophylline and mitraphylline in two Thai Mitragyna species and the investigation of their biological activity via opioid gene expression analysis.Scientific reports · 2025Article
- Kratom: A Narrative Review of the Possible Clinical Uses and Dangers of This Opioid-Like Plant.Cureus · 2024Review
- Non-invasive temporal interference brain stimulation reduces preference on morphine-induced conditioned place preference in rats.Scientific reports · 2024Article
- [Kratom-From natural remedy to addictive drug and back].Der Nervenarzt · 2024Review
- Kratom safety and toxicology in the public health context: research needs to better inform regulation.Frontiers in pharmacology · 2024Review
- Kratom withdrawal: Discussions and conclusions of a scientific expert forum.Drug and alcohol dependence reports · 2023Article
- Kratom's Emergence and Persistence Within the US Polydrug Epidemic.Current addiction reports · 2023Review
- Opioid replacement therapy with methadone or buprenorphine effects on male mice reproduction.Psychopharmacology · 2023Article
- Clinical Implications of Kratom (Current addiction reports · 2023Review
- Physiological dependence to mitragynine indicated by a rapid cross-dependence procedure with heroin-dependent mice.Psychopharmacology · 2022Article
- Review
- Searching for a Signal: Self-Reported Kratom Dose-Effect Relationships Among a Sample of US Adults With Regular Kratom Use Histories.Frontiers in pharmacology · 2022Article
- Adolescent kratom exposure affects cognitive behaviours and brain metabolite profiles in Sprague-Dawley rats.Frontiers in pharmacology · 2022Article
- Variations in mitragynine content in the naturally growing Kratom (Frontiers in plant science · 2022Article
- Mitragynine improves cognitive performance in morphine-withdrawn rats.Psychopharmacology · 2022Article
- Pentylenetetrazol-like stimulus is not produced following naloxone-precipitated mitragynine withdrawal in rats.Psychopharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOpiate addiction is a major health problem in many countries. A crucial component of the medical treatment is the management of highly aversive opiate withdrawal signs, which may otherwise lead to resumption of drug taking. In a medication-assisted treatment (MAT), methadone and buprenorphine have been implemented as substitution drugs. Despite MAT effectiveness, there are still limitations and side effects of using methadone and buprenorphine. Thus, other alternative therapies with less side effects, overdosing, and co-morbidities are desired. One of the potential pharmacotherapies may involve kratom's major indole alkaloid, mitragynine, since kratom (
methodsBased on the morphine withdrawal model, rats were morphine treated with increasing doses from 10 to 50 mg/kg twice daily over a period of 6 days. The treatment was discontinued on day 7 in order to induce a spontaneous morphine abstinence. The withdrawal signs were measured daily after 24 h of the last morphine administration over a period of 28 abstinence days. In rats that developed withdrawal signs, a drug replacement treatment was given using mitragynine, methadone, or buprenorphine and the global withdrawal score was evaluated.
resultsThe morphine withdrawal model induced profound withdrawal signs for 16 days. Mitragynine (5-30 mg/kg; i.p.) was able to attenuate acute withdrawal signs in morphine dependent rats. On the other hand, smaller doses of methadone (0.5-2 mg/kg; i.p.) and buprenorphine (0.4-1.6 mg/kg; i.p.) were necessary to mitigate these effects.
conclusionsThese data suggest that mitragynine may be a potential drug candidate for opiate withdrawal treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.